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Abstract
The objective of this study was to characterize the temporal variability of fluoroquinolone 
resistance mechanisms among Escherichia coli colonizing the gastrointestinal tract of hospitalized 
patients. Patients with new fluoroquinolone-resistant E. coli (FQREC) colonization were followed 
with serial fecal sampling until discharge or death. Genetic mechanism(s) of resistance for all 
FQREC isolates were characterized, including mutations in gyrA and parC and efflux pump 
overexpression. Of 451 subjects, 73 (16.2%) became newly colonized with FQREC. There was 
significant variability in regard to temporal changes in resistance mechanisms and levofloxacin 
MICs among isolates from individual patients. Compared to patients with transient colonization, 
patients with persistent colonization were more likely to have a urinary catheter (P=0.04), diarrhea 
(P=0.04), and a longer duration of hospitalization (22 and 9.0 mean days, respectively; P=0.01) 
prior to sampling. Our data demonstrate the significant variability of resistance mechanisms in 
colonizing E. coli isolates among hospitalized patients.
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The rapid increase in the prevalence of fluoroquinolone-resistant Escherichia coli (FQREC) 
in recent years is of significant public health concern (Lautenbach et al., 2004). The major 
mechanisms leading to FQ resistance in E. coli include 1) mutations in the genes encoding 
the drug targets DNA gyrase and topoisomerase IV, most commonly in the gyrA and parC 
genes in the quinolone resistance-determining region (QRDR), and 2) overproduction of the 
AcrAB-TolC drug efflux pump (Jacoby, 2005; Li and Nikaido, 2009).
In vitro studies characterizing the emergence of FQ resistance in E. coli have demonstrated 
that selection of resistance occurs in a stepwise fashion, with increasing numbers of 
mutations leading to correspondingly higher FQ minimum inhibitory concentrations (MICs) 
(Kern et al., 2000; Chang et al., 2007; Singh et al., 2012). In the clinical setting, studies have 
also suggested that MICs to FQs in E. coli are typically higher in organisms with a greater 
number of resistance mutations (e.g., in target enzymes or genes mediating efflux) (Komp 
Lindgren et al., 2003; Lautenbach et al., 2006a; Morgan-Linnell et al., 2009; Moon et al., 
2010). However, these studies have focused on isolates derived from clinical infections, 
whereas FQ resistance likely arises at the level of gastrointestinal tract colonization (Richard 
et al., 2001; Donskey, 2006).
Characterizing the stepwise accumulation of resistance mutations in colonizing E. coli 
isolates from individual patients is critical to enhanced understanding of the development of 
FQ resistance in the clinical setting, including informing potential strategies targeting 
specific resistance mechanisms to limit the emergence of FQREC. Therefore, we conducted 
this study to characterize the temporal changes in FQ resistance and resistance mutations 
among adult inpatients with new FQREC gastrointestinal tract colonization. In addition, we 
compared characteristics of patients who demonstrated transient FQREC colonization (i.e., 
FQREC colonization demonstrated on only one occasion) versus those with persistent 
colonization (i.e., multiple FQREC isolates over time).
2. Materials and methods
2.1. Study design and setting
This prospective cohort study was conducted at two hospitals in the University of 
Pennsylvania Health System (UPHS) in Philadelphia: the Hospital of the University of 
Pennsylvania (HUP), a 725-bed academic tertiary care medical center, and Penn 
Presbyterian Medical Center (PPMC), a 344-bed urban community hospital. As previously 
described (Lautenbach et al., 2006a; Lautenbach et al., 2009), three annual fecal surveillance 
surveys were performed hospital-wide at the two hospitals during the study years 2002, 
2003, and 2004. For the present study, target units were selected from the two hospitals 
based on high prevalence rates of FQREC characterized by the three surveys (two units at 
PPMC and four units at HUP). The selected units included general medicine, oncology, 
rehabilitation, and intensive care units.
Subsequently, each unit was surveyed for a 3-month time period, with all patients admitted 
to the target units eligible for inclusion in the present study cohort. On the first day of a unit 
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survey, all patients hospitalized on the unit at 8:00 AM were identified and approached, with 
subsequent enrollment in the study if informed consent was obtained. For those patients who 
agreed to participate, fecal samples via a perirectal swab were obtained and submitted to the 
HUP Clinical Microbiology Laboratory for processing. Patients were followed 
longitudinally and continued to have fecal samples submitted every 48 to 72 hours 
(depending on patient availability) until the time of hospital discharge or death. New 
patients admitted to the unit during the survey period were also eligible to be enrolled in the 
study. Any patient transferred to another unit of the hospital continued to be followed until 
the time of hospital discharge or death. At the end of the three months, all patients currently 
undergoing surveillance continued to be followed until the time of hospital discharge or 
death. However, no new patients were enrolled during the third month of the survey to allow 
for complete follow up of all patients already enrolled. Each patient was included as a 
subject only once, with only the first episode of eligibility included. The study was approved 
by the institutional review board of the University of Pennsylvania.
2.2 Data collection
Data were abstracted from the Pennsylvania Integrated Clinical and Administrative 
Research Database (PICARD) (Barton et al., 2005; Lee et al., 2009), which includes 
demographic, laboratory, pharmacy, and billing information. Information for all patients was 
collected on the following: baseline demographics, year of the surveillance culture, hospital 
of admission, transfer from another institution or nursing home, admissions to UPHS in the 
30 days prior to sampling, service location at the time of sampling (i.e., medical versus 
surgical), and number of hospital days prior to sampling. The presence of the following 
comorbid conditions was documented at the time of the sampling: diabetes mellitus, 
malignancy, renal insufficiency (creatinine 2.0 mg/dL or the requirement of dialysis), HIV 
infection, solid organ or hematopoietic stem cell transplant, neutropenia (absolute neutrophil 
count <500/mm3), significant cardiovascular disease (e.g., severe congestive heart failure), 
significant respiratory disease (e.g., severe chronic obstructive pulmonary disease, chronic 
bronchitis), and any surgical procedure performed in the 30 days prior to sampling. Data on 
the presence of a urinary catheter, central venous catheter, or diarrhea prior to the initial 
surveillance culture were collected for all patients. Furthermore, data on antimicrobial 
therapy, chemotherapy, and steroids or other immunosuppressive agents administered during 
the 30 days prior to fecal sampling was ascertained.
2.3. Microbiological methods
Detection of E. coli from fecal samples was performed as described previously (Lautenbach 
et al., 2006a; Lautenbach et al., 2009). Given the multi-step nature of development of FQ 
resistance in a given isolate, organisms with MICs in the susceptible but elevated range 
(e.g., with early single mutations) may be critical in explaining the emergence and 
dissemination of FQ resistance (Gales et al., 2000; Kern et al., 2000; Chang et al., 2007; 
Singh et al., 2012). As such, for the present study, low-level FQ resistance (i.e., reduced FQ 
susceptibility) and high-level FQ resistance were defined as a levofloxacin MIC 0.25 g/mL 
but <8 g/mL and 8 g/mL, respectively. The QRDR of gyrA and parC were amplified and 
sequenced as previously described (Lautenbach et al., 2006a; Lautenbach et al., 2009). 
Overexpression of AcrAB was measured indirectly by the organic solvent tolerance assay as 
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previously validated (White et al., 1997; Wang et al., 2001). Two sets of primers were used 
to detect the plasmid-encoded fluoroquinolone resistance gene qnr as previously described 
(Lautenbach et al., 2006a).The genetic relatedness of E. coli isolates was determined by 
molecular typing using pulsed field gel electrophoresis (PFGE) (Lautenbach et al., 2006a), 
with all results analyzed using the Fingerprinting II Informatix Software v 3.0 (Bio-Rad 
Laboratories, Inc., Hercules, CA) and interpreted according to established criteria (Goering 
and Tenover, 1997).
2.4. Statistical analysis
The incidence of new FQREC colonization during the study period was calculated, with 
three stages of FQREC colonization identified, as follows: 1) no FQREC colonization 
(levofloxacin MIC <0.25 μg/mL); 2) low-level FQREC colonization (levofloxacin MIC 0.25 
μg/mL but <8.0 μg/mL); and 3) high-level FQREC colonization (levofloxacin MIC ≥8 μg/
mL). For each patient with new FQREC colonization, resistance mechanisms (e.g., 
accumulation of mutations) of the isolates were described. For any patient with more than 
one FQREC isolate identified over time, all FQREC isolates were similarly characterized. 
Genetic mechanism(s) of resistance for all FQREC isolates were characterized by focusing 
specifically on mutations in gyrA and parC, as well as the presence of OST.
Characteristics of patients with colonization with one FQREC isolate (i.e., transient 
colonization) versus multiple FQREC isolates (i.e., persistent colonization) during the 
sampling period were compared, including demographic variables, comorbid conditions, and 
antimicrobial use in the 30 days prior to initial sampling. Continuous variables were 
compared using the Student’s t-test or Wilcoxon rank-sum test and categorical variables 
were compared using the χ2 or Fisher’s exact test. Bivariable analyses were then performed 
to determine the association between patient characteristics and colonization with more than 
one FQREC isolate during the sampling period. All statistical calculations were performed 
using commercially available software (STATA v11.0; StataCorp LP, College Station, 
Texas).
3. Results
During the study period, a total of 1,186 hospitalized patients were approached for 
enrollment (Figure 1). Of these, 522 (44.0%) provided informed consent and had an initial 
fecal swab obtained. Notably, there were no significant differences with regard to mean age, 
race and ethnicity, year of enrollment, and hospital of admission (i.e., HUP versus PPMC) 
when comparing patients who did and did not enroll in the study.
Of the 522 patients who had an initial sample obtained, 429 (82.2%) were hospitalized at 
HUP while 93 (17.8%) were hospitalized at PPMC. Subsequently, 516 patients had fecal 
specimens that revealed E. coli, of which 451 (87.4%) were FQ-susceptible. These 451 
patients who were initially colonized with FQ-susceptible E. coli represented the primary 
study cohort. These subjects underwent serial surveillance sampling during hospitalization 
with 73 (16.2%) having a subsequent culture positive for FQREC. Among these unique 73 
patients, there were a total of 98 E. coli isolates with FQ resistance during the sampling 
period, as follows: 53 (54.1%) isolates with low-level resistance (levofloxacin MIC 0.25 
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μg/mL but <8.0 μg/mL) and 45 (45.9%) isolates with high-level resistance (levofloxacin 
MIC ≥8 μg/mL). Molecular characteristics of these FQREC isolates are shown in Table 1. 
The median number of gyrA mutations for E. coli isolates with high-level resistance versus 
low-level resistance was 2.0 and 1.0, respectively (P<0.001). The median number of parC 
mutations for E. coli isolates with high-level resistance versus low-level resistance was 1.0 
and 0.0, respectively (P<0.001). The qnr gene was not detected in any study isolate. Finally, 
isolates with high-level resistance were more likely to be OST-positive compared to isolates 
with low-level resistance (P<0.001).
A total of 14 (19.2%) of the 73 patients with new colonization with FQREC had >1 FQREC 
culture during the sampling time period. Among these 14 unique patients, there were 39 
isolates with FQ resistance (low-level and high-level). Temporal changes in levofloxacin 
MIC values, resistance mechanisms, as well as clonal relationships among the 14 patients 
with >1 FQREC isolate during sampling are shown in Table 2. Thirty-seven out of 39 
isolates were successfully characterized by PFGE. Comparison of the 37 isolates as a group 
demonstrated no evidence of clustering during the study period (i.e., indication of an 
outbreak). Subsequently, the variability in PFGE patterns within sample sets for each patient 
was assessed, with five patients demonstrating clonally related isolates (C, K, M, Q, V; 
Table 2).
Characteristics of patients with >1 FQREC isolate during sampling are compared to those 
with only one FQREC isolate in Table 3. Notably, patients with persistent as opposed to 
transient colonization with FQREC during the sampling period were more likely to have 
received cefepime (50.0% and 17.0%, respectively; P=0.02) and vancomycin (50.0% and 
20.3%, respectively; P=0.04) in the 30 days prior to sampling. These patients were also 
more likely to have had a urinary catheter (78.6% and 44.1%, respectively; P=0.04) and 
diarrhea (28.6% and 6.8%, respectively; P=0.04) present prior to the initial culture.
4. Discussion
In this 3-year study, we found that 73 (16.2%) patients became newly colonized with 
FQREC during hospitalization. Of these 73 patients, 14 (19.2%) had >1 FQREC isolate on 
serial surveillance cultures. Notably, there was significant variability in regard to temporal 
changes in both resistance mechanisms, as well as levofloxacin MICs, among isolates from 
individual patients. There was little evidence for persistent colonization with the same 
FQREC clone among patients with >1 FQREC isolate on serial cultures.
The present study, to our knowledge, is the first to characterize longitudinal changes in 
resistance mechanisms in FQREC isolates from the same patient during hospitalization. 
Specifically, we found that the majority of patients who were newly colonized with FQREC 
had only one resistant isolate during serial surveillance performed during hospitalization. In 
addition, all of these patients had surveillance cultures that were positive for FQ-susceptible 
E. coli. It is possible that these 59 patients demonstrated resolution of FQREC colonization, 
or that they were predominantly colonized with FQ-susceptible strains which dominated on 
subsequent samplings such that the previous FQREC isolate could not be identified.
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In contrast, 14 patients who developed new FQREC colonization had more than one 
resistant isolate during the sampling period. Compared to patients who had only one FQREC 
isolate during surveillance, these patients were more likely to have had a urinary catheter or 
diarrhea, as well as a longer duration of hospitalization, prior to the sampling date. All of 
these factors, notably instrumentation (e.g., indwelling catheters) may have increased the 
risk of developing new and persistent gastrointestinal and/or urinary tract colonization with 
FQREC. Furthermore, patients with more than one FQREC isolate were more likely to have 
received cefepime and/or vancomycin in the 30 days prior to sampling. It is likely that 
receipt of these antimicrobial agents reflected greater severity of illness overall in 
hospitalized patients with new FQREC colonization.
Interestingly, only 4 of these patients (subjects #2, 7, 10, and 12) had isolates that progressed 
longitudinally from no FQREC colonization to low-level FQREC and ultimately to high-
level FQREC. The progression in FQ resistance evidenced in our study usually involved 
acquisition of an additional gyrA mutation and/or a parC mutation as opposed to changes in 
efflux pump overexpression. However, as the low-level and high-level resistant isolates in 
these 4 individual patients were not clonally related by PFGE, it is unlikely that the temporal 
increase in levofloxacin resistance was due to colonization with E. coli strains with high 
mutation rates (e.g., allowing for relatively rapid development of full FQ resistance).
Rather than de novo mutations accounting for the observed increase in the number of 
resistance mechanisms, it is likely that patients were colonized with more than one FQREC 
strain during hospitalization. Indeed, a previous study performed at the same institution 
(Lautenbach et al., 2006b) demonstrated that several subjects who were recently discharged 
from the hospital were colonized with more than one FQREC strain during the surveillance 
period. Along these lines, FQ-susceptible strains were detected between that of FQREC 
isolates for the majority of the 14 patients in the present study. Furthermore, some patients 
had more than one E. coli strain with high-level FQ resistance as determined by differences 
in resistance mechanisms and lack of clonality (i.e., subjects #4, #7, and #11). These 
findings suggest that patients may be colonized with multiple E. coli strains with varying 
levels of FQ resistance, and further studies are needed to identify determinants of 
subsequent infection with FQREC as opposed to FQ-susceptible strains in multiply-
colonized patients.
Finally, 5 (35.7%) of the 14 patients had a clonally-related strain detected on more than one 
sample during serial surveillance (subjects #2, 5, #6, #8, #10) This may have reflected 
variability in which colonies were sampled during processing. However, the results suggest 
that duration of colonization and/or predominance of a particular FQREC clone may 
significantly vary in an individual patient, and future studies will need to evaluate potential 
risk factors, including specific resistance mechanisms, for persistence of a particular 
colonizing FQREC strain in hospitalized patients.
There are potential limitations of our study. Selection bias is a potential concern; however, 
although only ~45% of eligible subjects were enrolled, participants and nonparticipants were 
similar in regard to demographic characteristics. Sampling variability may have limited the 
detection of all colonizing FQREC isolates from a single patient. Finally, the present study 
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was conducted in a single healthcare system, and these results may not be generalizable to 
other institutions.
In conclusion, the results of our study highlight the significant variability in resistance 
mechanisms in colonizing E. coli isolates among hospitalized patients. The emergence and 
persistence of FQ resistance is complex, and future studies are need to evaluate selection 
pressure for specific resistance mechanisms during hospitalization, as well as risk factors for 
infection with FQREC strains in multiply-colonized patients.
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resistancec 32 40 (93.0%) 2 (2, 2) 34 (79.1%) 1 (1, 1) 25 (58.1%) 1: 8 (19.0%)
(n=43) 2: 17 (40.5%)
3: 17 (40.5%)
Low-level 0: 12 (24.5%)
resistanced 0.38 32 (65.3%) 1 (0, 1) 3 (6.1%) 0 (0, 0) 10 (20.4%) 1: 30 (61.2%)
(n=49) 2: 7 (14.3%)
3: 0 (0.0%)
MIC = minimum inhibitory concentration; OST = organic solvent tolerance; IQR = interquartile range.
a
6 isolates without information on mutations.
b
Median levofloxacin MIC by Etest.
c
Levofloxacin MIC 8 g/mL.
d
Levofloxacin MIC 0.25 g/mL but <8 g/mL.
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1 3 Susc. 0-5
Resistant 7 0.75 Ser83Leu Neg Neg A
9 Susc. 9-41
Resistant 44 0.75 Neg Neg Neg B
3 Susc. 46-52
2 8 Susc. 0-19
Resistant 21 0.25 Ser83Leu Neg Pos C
4 Susc. 24-31
Resistant 33 0.75 Ser83Leu Neg Pos D
4 Susc. 35-42
Resistant 45 0.25 Asp87Tyr Neg Pos C
5 Susc. 47-56
Resistant 59 32 Ser83Leu;Asp87Gly Ser80Ile Pos E
3 4 Susc. 0-10
Resistant 12 0.38 Ser83Leu Neg Neg F
Resistant 14 0.25 Asp87Tyr Neg Neg G
6 Susc. 17-28
4 6 Susc. 0-14
Resistant 17 ≥ 32 Ser83Leu; Asp87Tyr Ser80Arg; Glu84Val Neg H
7 Susc. 19-33
Resistant 35 ≥ 32 Ser83Leu; Asp87Gly Ser80Ile; Glu84Gly Pos I
7 Susc. 38-52
Resistant 54 0.25 Asp87Tyr Ser80Ile Neg J
5 6 Susc. 0-12
Resistant 14 ≥ 32 Ser83Leu; Asp87Tyr Ser80Arg; Glu84Val Pos K
1 Susc. 17
Resistant 19 ≥ 32 Ser83Leu,Asp87Asn Neg Pos K
4 Susc. 21-31
Resistant 33 0.5 Ser83Leu Neg Neg K
1 Susc. 35
6 2 Susc. 0-2
Resistant 4 ≥ 32 Ser83Leu; Asp87Gly Neg Pos L
Resistant 7 0.25 Asp87Tyr Neg Pos M
Resistant 9 0.25 Asp87Tyr Neg N/A M
8 Susc. 11-28


























7 3 Susc. 0-4
Resistant 7 1 Neg Neg Neg N
2 Susc. 9-11
Resistant 14 ≥ 32 Ser83Leu; Asp87Asn Ser80Ile Neg O
Resistant 16 ≥ 32 Ser83Leu; Asp87Asn Ser80Ile; Presentc Pos P
Resistant 18 ≥ 32 Ser83Leu,Asp87Tyr Ser80Ile Neg N/A
8 1 Susc. 0
Resistant 2 ≥ 32 Ser83Leu; Asp87Asn Ser80Ile Pos Q
4 Susc. 4-11
Resistant 14 0.125 N/A N/A N/A R
Resistant 16 ≥ 32 Ser83Leu,Asp87Asn Presentc Pos Q
Resistant 18 ≥ 32 Ser83Leu; Asp87Asn Ser80Ile Pos Q
9 1 Susc. 0
Resistant 2 ≥ 32 Ser83Leu,Asp87Asn Ser80Ile Neg S
1 Susc. 5
Resistant 9 0.75 Ser83Leu Neg Neg T
3 Susc. 12-16
10 14 Susc. 0-41
Resistant 43 0.19 Neg Neg Pos U
1 Susc. 46
Resistant 53 ≥ 32 Ser83Leu; Asp87Asn Neg Neg V
Resistant 55 ≥ 32 Ser83Leu; Asp87Asn Neg Neg V
2 Susc. 60-63
11 1 Susc. 0
Resistant 4 8 Ser83Leu; Asp87Asn Ser80Ile Neg W
14 Susc. 6-42
Resistant 46 ≥ 32 Ser83Leu; Asp87Asn Ser80Ile; Glu84Val Neg X
12 2 Susc. 0-3
Resistant 6 0.38 Neg Neg Neg Y
4 Susc. 8-17
Resistant 20 0.5 Neg Neg Neg Z
Susc. 22
Resistant 24 ≥ 32 Neg Ser80Ile Neg N/A
13 2 Susc. 0-2
Resistant 5 0.25 1gyrA AA
Resistant 7 0.25 1gyrA BB
14 3 Susc. 0-5


























Resistant 7 0.5 Ser83Leu Neg Neg CC
4 Susc. 17-21
Resistant 26 0.38 Ser83Leu; Asp87Asn Neg Pos DD
1 Susc. 28
Susc. = susceptible; MIC = minimum inhibitory concentration; OST = organic solvent tolerance; PFGE = pulsed field gel electrophoresis; Neg = 
negative; Pos = positive; N/A = not available.
a
Levofloxacin MIC by Etest.
b
Isolates with the same designated letter are considered to be clonally related.
c
A single parC mutation was present, but unable to be further characterized.
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Age, mean years (SD) 63.5 (18.5) 61.5 (13.3) 0.62
Female sex 31 (52.5) 6 (42.9) 0.56
Non-white race 26 (44.1) 6 (42.9) >0.99
Duration of hospitalization prior to
culture date, mean days (SD) 9.0 (13.8) 22 (33.5) 0.01
PPMC admission 15 (25.4) 2 (14.3) 0.50
Year of cultureb 36 (61.0) 5 (35.7) 0.13
Admitted from a nursing home 5 (8.5) 0 (0.0) 0.58
Transferred from another hospital 12 (20.3) 2 (14.3) >0.99
UPHS admit ≤30 days prior to
culture date 22 (37.3) 5 (35.7) >0.99
Surgical service 9 (15.3) 3 (21.4) 0.69
Urinary catheter 26 (44.1) 11 (78.6) 0.04
Mechanical ventilation 13 (22.0) 5 (35.7) 0.31
Central venous catheter 28 (50.0) 11 (78.6) 0.07
Diarrhea present 4 (6.8) 4 (28.6) 0.04
Diabetes mellitus 15 (25.4) 1 (7.1) 0.17
Neutropenia 0 (0.0) 0 (0.0) ….
Cirrhosis 3 (5.1) 1 (7.1) >0.99
HIV 1 (1.7) 1 (7.1) 0.35
Malignancy 13 (22.0) 5 (35.7) 0.31
Transplant 4 (7.1) 2 (15.4) 0.32
Renal insufficiency 13 (22.0) 0 (0.0) 0.06
Surgical procedure ≤30 days prior
to culture date 15 (25.4) 6 (42.9) 0.21
Receipt of immunosuppression ≤30
days prior to culture date 9 (15.3) 1 (7.1) 0.68






















Receipt of antimicrobial therapy ≤30
days prior to culture datec
Levofloxacin 11 (18.6) 0 (0.0) 0.11
Gentamicin 1 (1.7) 2 (14.3) 0.09
Cefepime 10 (17.0) 7 (50.0) 0.02
Flagyl 8 (13.6) 5 (35.7) 0.11
Vancomycin 12 (20.3) 7 (50.0) 0.04
Piperacillin-tazobactam 0 (0.0) 1 (7.1) 0.19
Any antibiotic 25 (42.4) 10 (71.4) 0.07
SD = standard deviation; PPMC = Penn Presbyterian Medical Center; UPHS = University of Pennsylvania Health System.
a




Only antimicrobial agents with P<0.20 are shown.
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